Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTRA-2112 for intestinal malabsorption in preterm infants
NL-OMON46903Phase 3Active, not recruiting
- Sponsor
- Nutrinia
- Start
- Oct 2016
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of elgn-gi in intestinal malabsorption and feeding intolerance (3 arms), sponsored by Nutrinia. Primary endpoints: Days to full enteral feeding and Sub-study sugar absorption test. Started Oct 2016; status: active, not recruiting.
02
Drugs
elgn-gi
03
Conditions
intestinal malabsorptionfeeding intolerance
Beyond the preview
Go deeper on NL-OMON46903.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46903.